Dr Mostafa - Working in the lab_16-9

Fund local research

When you donate to fund cancer research, you invest in a brighter future for Queenslanders with cancer.

Cancer Council Queensland is committed to ensuring no Queenslander faces cancer alone. We’re also dedicated to investing in lifesaving, local research to better detect and treat cancer.

Your generous donations help us support the brightest minds in cancer research. Together, we can fund local research that drives global breakthroughs. We make this possible by directly funding early career researchers who are on the front-line of clinical innovations in cancer detection and treatment.

This page covers
Your donation makes a real impact

Contributions go towards world-class research, prevention programs and support service.

The Next Generation Cancer Research Fellowship

The Cancer Council Queensland Next Generation Cancer Research Fellowships replace our Accelerating Collaborative Cancer Research Grants scheme and are focused on funding early career cancer researchers who are on the front-line of clinical innovations and breakthroughs in cancer detection and treatment.

Meet the current Next Generation Cancer Research Fellowship recipients

Our inspiring fellowship recipients are creating hope and innovating in a way that could change the future for a number of people with cancer. Here are the doctors at the front line of cancer research.

Dr Mostafa Kamal Masud

Dr Masud from The University of Queensland is conducting cancer research focused on developing a device which, using nanoengineered structures, aims to make it possible to detect early-stage ovarian cancer within two hours at a GP clinic.

Dr Jasmin Straube

Dr Jasmin Straube from QIMR Berghofer is researching vulnerabilities in leukemic stem cells carrying poor prognostic mutations. Her work will play a critical role in improving outcomes for patients with myeloid blood cancer.

Dr Mathias Seviiri

Dr Mathias Seviiri, also from QIMR Berghofer, is tackling the complex landscape of skin cancer. His research aims to unravel the complex relationships between genetics, treatment responses, and adverse events in patients undergoing treatment for melanoma and keratinocyte cancers.

Dr Melanie L Plinsinga

Dr Plinsinga, from Griffith University, is conducting research focused on improving the identification, prevention and management of chronic conditions such as lymphoedema and cancer-related pain in cancer survivors. Her work aims to enhance quality of life through targeted interventions and support strategies for people affected by cancer.

Dr Taskeen Janjua Khan

Dr Janjua Khan, from The University of Queensland, is conducting research focused on developing ultra-small silica nanoparticles to deliver chemotherapy drugs directly to glioblastoma tumours. This approach aims to improve treatment effectiveness while reducing side effects for people living with brain cancer.

Your contribution will be recognised

In addition to making the next big breakthrough possible, your contribution will also be recognised with:

  • Exclusive co-branding and naming rights for one of four fellowships awarded each year.
  • Promotional and PR opportunities as the research activity progresses.
  • Ongoing exclusive research updates directly from the research team you’re funding.

Ready to fund important cancer research? Talk to us.

Both businesses and individuals are welcome to enquire.

Previously awarded grants in action

Some of our previously awarded grants have helped fund:

  • A University of Queensland cancer research project looking at oesophageal cancer, a disease that currently has very few therapeutic options. The project, running until 2026, will undertake a complex assessment of PET/CT scans and pathology slides, using deep learning computational methods to identify new image markers reflective of the tumour profile. Researchers then aim to develop a risk prediction model that complements current patient diagnostics and provides improved precision medicine.
  • A University of Queensland cancer research project that will undertake the world’s first clinical trial of a central line lock that may prevent complications such as infections, blood clots and line blockage for children with cancer. Find out more.
  • A project at the Frazer Institute (University of Queensland), where researchers have used groundbreaking new technologies to uncover molecular clues that help predict which melanoma patients are most at risk of dying from the disease. By analysing thousands of genes, DNA mutations, and tiny biomarkers circulating in the blood, the team has identified clear patterns that distinguish patients whose melanoma became deadly from those who survived. This work could lead to more accurate tools for identifying high risk patients early, helping clinicians tailor treatment and improve outcomes.
  • A project at The Council of the Queensland Institute of Medical Research (QIMR Berghofer) that set out to understand why some people with lung cancer benefit from immunotherapy while others do not. Using advanced genetic technologies, the research team analysed lung cancer samples in new ways, not just looking at DNA and RNA, but also examining chemical changes to the DNA (called methylation) and tiny particles released by tumours into the blood. These approaches helped to identify potential markers that may predict how a patient will respond to immunotherapy and could improve future lung cancer tests.